Date post: | 17-Jan-2016 |
Category: |
Documents |
Upload: | gordon-small |
View: | 213 times |
Download: | 0 times |
January 2006
Forward Looking Statements
Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward -looking statements. Such statements, based as they are on the current expectations of management of Chemokine, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Chemokine's control. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Chemokine does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, as well as other risks included in Chemokine's preliminary prospectus under the heading " risk factors", which you are urged to read. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation . These statements speak only as update of the date they are made and Chemokine is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.
1
COMPANY AT A GLANCE
1
• Biotechnology company with products
• OTCBB: CHKT
• Shares: 42 million
• 52 weeks: $0.8 – 1.30
• Market Cap. $45 million
• Well funded and Sufficient funds on hand for Two lead drugs to the end of Phase II trials
• Also trades on Toronto: CTI
Chemokines are a new and explosive drug development field
Evidence:
1- November 2005 Pfizer buys chemokine program of Incyte for $800 million
2- Summer 2004 Amgen buys First Chemokine company(Tularik) for $1.2 billion
3- Summer 2003 Millennium Buys Leukocytes (chemokine-based) for $600 million
3
What are Chemokines?
Chemokines: New Class of Cytokines
Epogen, Neupogen,Avonex, Intron
$20B
Fusion (first chemokine-based drug). Roche/Trimeris
$1B
Cytokines Chemokines
4
Same Market Potential
Product Pipeline
5
Drug Stage of Development
Research Animal Human Human Human MarketLab Testing Testing Phase I Phase II Phase III
CTCE-9908
CTCE-0214
CTCE-0324
CTCE-0422
CTCE-0501
Cancer
Immune System Booster
Vascular Disease
Anti-Infection
Stroke
Metastasisequalsdeath
6
Product # 1:CTCE-9908
Cancer Relapses, due to Metastasis
32
• Almost all cancer deaths are due to cancer metastasis
• A new approach has taken by us whichStops the spread of cancer throughInhibition of cancer metastasis process
Cancer Relapse Due to Metastasis
1.
Cancer cells detach and migrate to blood vessel
2.
Cancer cells migrate to tissue with a high SDF-1 concentration
3.
Cancer cells accumulate and form new tumour
Lung
Liver
Bone
Primary tumour
7
CXCR4 – A Validated Target
Role established in metastasis of several types of cancer, Muller et al, Nature, 2001
> 2,000 publications on CXCR4200 related to cancer
Many independent labsworking on CXCR4
Cancer cell
CXCR4
8
CTCE-9908 Targeting CXCR4
The only known natural chemokine for CXCR4
An antagonist that blocks SDF-1 binding to CXCR4, preventing the formation of metastastic tumours
SDF-1
CTCE-9908
Cancer cell
9
CXCR4
CTCE-9908 Preclinical Findings
Lung cancer68%
Bone cancer67%
Prostate cancer61%
Average65% ResponseRate
12
Skin cancer65%
CTCE-9908 Phase I Results
Volunteers n = 24 (18 male, 6 female)
Single dose
Maximum dose tested 5 mg/kg
No dose limiting toxicity
12
CTCE-9908 Next Step to Added Value
14
Chemokine to start Phase Ib/II clinical trials in the Q1, 2006
Expected results in Q4, 2006
16
Bloodequalslife
Product # 2:CTCE-0214
Blood Cell System Disorders
Healthy state Suppressed state(Chemotherapy, AIDS, etc.)
Rate of mobilization no longer fully replenishes WBCs and platelets
Platelets
Fewer WBCs and platelets results in infections/fatigue and other medical complications
Bone marrow
Stem cells
Spleen
White blood cells (WBC) 17
Blood vessel
CTCE-0214 Targeting CXCR4
The only known natural chemokine for CXCR4
• A CXCR4 agonist
• Mobilizes stem cells from bone marrow and spleen
• Assists in the differentiation of stem cells into white blood cells and platelets
CXCR4
SDF-1
CTCE-0214
Stem cells and
White Blood Cells(WBC)
• Mobilizes WBCs and platelets
18
CTCE-0214 Clinical Trial Phase I
20
Conducted in Tacoma/Seattle, Washington under US-INDEnrolled 24 volunteer subjectsRandomized, double-blind, placebo controlled
Results: The drug showed to be safe and well tolerated
Preliminary efficacy was observed
CTCE-0214 Clinical Phase I Efficacy
Safety established – No serious adverse events
Dose dependantresponse at 6, 12 and24 hours
Warrants advancing toadditional clinical trials
300%Increasein WBCs
21
CTCE-0214 Market Potential
White blood cell products represent US$3 B
Projected to grow to US$4.5 B by 2008
Dominated by Neupogen® of Amgen
• Takes at least 4-5 days for response on average and up to 14 days for full recovery
CTCE-0214 has fast action
• Potential to enhance production and infection fighting capacity of white blood cells in all patients
• Potential to act synergistically with Neupogen®
22
CTCE-0214 Next Step to Value
23
• We have started the second Phase of clinical trialsPhase Ib/II in Dec. 2005
• The work is being conducted in Tacoma, Washington
• Results are expected in the Summer of 2006
26
Peripheral Arterial Disease
Product #3
CTCE-0324
Peripheral Arterial Disease (PAD)
26
Causes:DiabetesObesityAgeAtherosclerosis
Current Treatment:AmputationPhysiotherapyExerciseAspirin 10 million patients
in the USA
Our Drug Generates New Blood Vessels
27
Neovascularization occurswith CTCE-0324 compound
Control - Untreated
Main Vasculature After 2 Weeks
Market Potential: $10 Billion
Company Management and Advisors
30
Hassan Salari, PhD - Founder, President & CEOFounding President and CEO Inflazyme PharmaFormer Professor of Medicine, UBC
Walter Korz - Vice President, Drug DevelopmentFormer Manager of clinical development Angiotech
Malcolm Moore, D. Phil. (Medical Advisor)Professor Memorial Sloan Kettering Cancer Institute, NYCo-discoverer of Neupogen for Amgen
Shahin Rafii, M.D. (Medical Advisor)Howard Hughes Medical Institute Award Recipient, Cornell Medical Center, NY
Edward Ball, M.D. (Medical Advisor)Professor University of California San DiegoCo-founder Medarex, NJ
Comparables
Company Stage Market Cap.
Chemokine (CHKT) Phase I/II $45 million
Point Ther (POTP) Phase II $100 millionOxigene (OXGN) Phase II $115 million
AnorMED (AOM) Phase II $130 million
Curis (CRIS) Phase II $215 million
Aastrom Bio (ASTM) Phase II $285 million
Stem Cells Inc (STEM) Phase II $325 million
30
• 2005 Pfizer and Incyte Pharmaceuticals. Incyte finishes Phase II (IBD). Pfizer license the product for $800 million
• 2004 Amgen and Tularik. Tularik finishes Phase II (arthritis). Amgen buys Tularik for $1.2 Billion
• 2003 Millennium Pharmaceuticals and Leukocytes. Leukocytes finishes Phase II (transplant). Millennium buys leukocyte for $600 million
• Chemokine Therapeutics, 16 patents, lead in cancer, blood disorder, vascular, 9-12 months away from finishing Phase II >>>>>>>>>>> $$$
Exit Strategy (Partnership / M&A)
The Company in Review
2
• Biotechnology company with 5 products– Two drugs in Phase II in 2006– One drug entering IND in 2006– Two products in animal studies
• 16 patents
• Licensing or M & A in the horizon
• Publicly Traded – OTCBB: CHKT and TSX: CTI
• Visit our website: www.CHKT.com